Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules
Authors' conclusion
In young patients with ITNs, the Afirma GSC demonstrated an excellent negative predictive value when defining a thyroid nodule result by histology or clinical follow-up.
Study context
- Population
- Patients <21 years (aged 9 to 20 years) with cytologically indeterminate thyroid nodules referred for molecular testing, with histopathology or 2 years' clinical follow-up
- Participants
- 49 indeterminate thyroid nodules (ITNs)
- Outcome
- Afirma GSC test performance
Methodological detailsretrospective, real-world setting
- Retrospective
- Real-world setting
Performance
As reported in the abstract
| Test or model | Sensitivity | Specificity | NPV |
|---|---|---|---|
| Afirma Genomic Sequencing Classifier (GSC) | 100% [95% CI, 77-100] | 86% [95% CI, 70-95] | 100% [95% CI, 88-100] |
Afirma Genomic Sequencing Classifier (GSC)
Sensitivity100% [95% CI, 77-100]
Specificity86% [95% CI, 70-95]
NPV100% [95% CI, 88-100]
- GSC-B results
- 30
- GSC-S results
- 19
- GSC-S malignant (true positive)
- 14 (73.7%)
- GSC-S benign (false positive)
- 5 (26.3%)
- GSC-B cases benign (true negative): histologically / clinically
- 9 / 21
Further findings
Genomic alterations in GSC-B samples
- Genomic alterations were not detected in the 30 GSC-B samples
- 0
Histology of 14 malignant samples
- PTC
- 9
- Oncocytic carcinoma
- 1
- Noninvasive follicular thyroid neoplasm with papillary-like nuclear features
- 1
- FTC
- 3
Original publication
Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. Published 12 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →